Area of research
Hematology · Genetics
Research interest
Research interests include Medicine, Haemophilia, Haemophilia A, Internal medicine, Physical therapy, and Incidence (geometry).
Trends in Treatment of Severe Haemophilia and Impact on Inhibitor Assessment by the EUHASS Registry
Bleeding control improves after switching to emicizumab: Real‐world experience of 177 children in the PedNet registry
Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS)
Low dose emicizumab prophylaxis in haemophilia a patients: A pilot study from India
Magnetic resonance imaging evidence for subclinical joint bleeding in a Dutch population of people with severe hemophilia on prophylaxis
The efficacy of the entire-vial dosing of emicizumab: Real-world evidence on plasma concentrations, bleeds, and drug waste
Subclinical synovial proliferation in patients with severe haemophilia A: The value of ultrasound screening and biochemical markers
Dilemmas on emicizumab in children with haemophilia A: A survey of strategies from PedNet centres
Inhibitor development according to concentrate in severe hemophilia: reporting on 1392 Previously Untreated Patients from Europe and Canada
Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A
European principles of care for women and girls with inherited bleeding disorders
Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review
Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study
Adherence to prophylaxis and its association with activation of self‐management and treatment satisfaction
Shortening the Haemophilia Activities List (HAL) from 42 items to 18 items
Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study
Long‐term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B‐YOND extension study
A feasibility study on two tailored interventions to improve adherence in adults with haemophilia
Evaluating international Haemophilia Joint Health Score (HJHS) results combined with expert opinion: Options for a shorter HJHS
The experiences and attitudes of hemophilia carriers around pregnancy: A qualitative systematic review
Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A
Review of immune tolerance induction in hemophilia A
BAY 94‐9027, a PEGylated recombinant factor VIII, exhibits a prolonged half‐life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies
Long-Term Outcome after Joint Bleeds in Von Willebrand Disease Compared to Haemophilia A: A Post Hoc Analysis
Measuring activities and participation in persons with haemophilia: A systematic review of commonly used instruments
Evaluating outcome of prophylaxis in haemophilia: objective and self‐reported instruments should be combined
Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B
Inhibitor development in haemophilia according to concentrate
Using the Haemophilia Joint Health Score for assessment of teenagers and young adults: exploring reliability and validity
Haemophilia Joint Health Score in healthy adults playing sports